Valion Bio, Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Valion Bio announced continued discussions with U.S. government agencies (BARDA, NIAID, AFRRI, DoW) and Ukraine's Ministry of Health regarding Entolimod for Acute Radiation Syndrome preparedness and potential Strategic National Stockpile inclusion; demonstrated 200-fold manufacturing scale-up through wholly owned subsidiary Velocity Bioworks achieving ~1.3 million potential human doses at 50-liter fermentation scale; and plans physician-sponsored studies evaluating Entolimod in oncology supportive care for neutropenia. No funding, procurement, or stockpiling agreements have been executed.
Why this rating
Company-owned manufacturing achieving 200-fold scale-up and active government engagement represent meaningful strategic advances for a $4M market-cap biotech. However, no executed agreements, funding, or revenue materialize yet. Material relative to size but execution risk remains high.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.